“Lymphoma” covers many biologically different diseases
Hodgkin and non-Hodgkin lymphomas include many subtypes with different natural histories and treatment. Architecture, immunophenotype and molecular findings may be needed to classify tissue correctly.
The plan combines subtype, stage, tumour burden, symptoms, age, health and previous treatment. Some indolent lymphomas can be observed; aggressive disease may need prompt multi-drug treatment.
A small needle sample may not preserve lymph-node architecture. Ask whether the material is sufficient for confident classification and future testing.
Who may be considered?
Specialist review may help when the source diagnosis and treatment timeline raise a practical question about lymphoma subtype, stage and treatment sequence.
- A new lymphoma diagnosis requiring expert pathology confirmation.
- Unclear subtype or discordant biopsy and imaging findings.
- Relapsed or refractory disease needing a new biopsy and treatment map.
- A transplant or CAR-T referral question.
- A patient comparing standard therapy with a clinical trial.
What the specialist team must confirm
Review includes the original pathology and tissue, immunohistochemistry, flow or molecular tests, PET/CT or other staging studies, symptoms, blood tests, viral screening, heart function when relevant and the full response history.
Key points for this treatment
From tissue diagnosis to response-adapted treatment
The pathway changes according to indolent or aggressive biology, treatment intent and prior response.
Remission, surveillance and later-line options
After treatment, response is assessed with disease-appropriate criteria and imaging timing. Routine surveillance should avoid unnecessary tests while maintaining symptom awareness.
At relapse, biopsy may be important because biology can change. Options can include another systemic regimen, radiotherapy, transplant, CAR-T or a trial depending on subtype and prior therapy.
Limits, burdens and realistic expectations
Therapy can cause infection, marrow suppression, neuropathy, heart or lung toxicity, infertility and later cancers. PET findings can reflect inflammation, and remission does not eliminate relapse risk. More treatment is not always better for indolent disease.
Rapidly enlarging masses, airway symptoms, severe abdominal pain, new neurologic deficits, fever during therapy or tumour-lysis concerns need urgent local care.